Clinical profiles of hypertensive patients in whom it is worth to consider combination of therapy with telmisartan and hydrochlorothiazide Review article

Main Article Content

Wioletta Wydra
Marek Kuch

Abstract

Telmisartan is a modern long-acting sartan characterized by metabolic activity, particularly indicated for patients with high cardiovascular risk. Joining telmisartan low dose thiazide diuretic (hydrochlorothiazide) improves the efficacy of antihypertensive therapy without significantly increasing the incidence of side effects. Combination therapy of telmisartan and hydrochlorothiazide is available as a combined preparation, which simplifies the treatment and increases therapeutic compliance.

Article Details

How to Cite
Wydra, W., & Kuch , M. (2016). Clinical profiles of hypertensive patients in whom it is worth to consider combination of therapy with telmisartan and hydrochlorothiazide. Medycyna Faktow (J EBM), 9(3(32), 249-254. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2231
Section
Articles

References

1. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur. Heart J. 2013; 34: 2159-2219.
2. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Nadciśnienie Tętnicze w Praktyce 2015; 1(1): 1-70.
3. Charakterystyka produktu leczniczego. Telmisartan.
4. Neutel J.M.: Ambulatory blood pressure monitoring to assess the comparative efficacy and duration of action of a novel new angiotensin II receptor blocker-telmisartan. Blood Press. 2001; 10(4): 27-32.
5. Lacourcière Y., Tytus R., O’Keefe D. et al.: Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy. J. Hum. Hypertens. 2001; 15(11): 763-770.
6. Lacourcière Y., Martin K.: Comparison of a fixed-dose combination of 40 mg telmisartan plus 12.5 mg hydrochlorothiazide with 40 mg telmisartan in the control of mild to moderate hypertension. Am. J. Ther. 2002; 9(2): 111-117.
7. Parati G., Bilo G., Redon J. et al.: The effects of telmisartan alone or with hydrochlorothiazide on morning and 24-h ambulatory BP control: results from a practice-based study (SURGE 2). Hypertens. Res. 2013; 36(4): 322-327.
8. Kjeldsen S.E., Schmieder R.E., Unger T. et al.: Telmisartan and hydrochlorothiazide combination therapy for the treatment of hypertension. Curr. Med. Res. Opin. 2010; 26(4): 879-887.
9. The ONTARGET Investigators: Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. N. Engl. J. Med. 2008; 358: 1547-1559.
10. Inoue T., Morooka T., Moroe K. et al.: Effect of telmisartan on cholesterol levels in patients with hypertension – Saga Telmisartan Aggressive Research (STAR). Horm. Metab. Res. 2007; 39(5): 372-376.
11. Vitale C., Mercuro G., Castiglioni C. et al.: Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc. Diabetol. 2005; 4: 6.
12. Morimoto T., Gandhi T.K., Fiskio J.M. et al.: An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J. Eval. Clin. Pract. 2004; 10(4): 499-509.
13. Widecka K., Grodzicki T., Narkiewicz K.: Zasady postępowania w nadciśnieniu tętniczym – 2011 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze 2011; 15(4): 211-235.
14. Poon I.O.: Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment. Pharmacotherapy 2008; 28: 366-375.
15. Yusuf S., Diener H., Sacco R.L. et al.: Telmisartan to prevent recurrent stroke and cardiovascular events (PRoFESS). N. Engl. J. Med. 2008; 359: 1225-1237.
16. ATHOS Study Group: Telmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring study. Am. J. Geriatr. Cardiol. 2006; 15(3): 151-160.